Ricky Rusydi Satriawan

Ricky Rusydi Satriawan

Auto-generated profile, based on publicly available information

Ricky Rusydi Satriawan

Department of Neurosurgery, Faculty of Medicine, University of Indonesia, Jakarta, DKI Jakarta

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2025 in F1000Research
Verified
Journal Article
Open access
PDF file
RARenindra Ananda Aman
Renindra Ananda Aman
MPMohammad Galih Pratama
Mohammad Galih Pratama
RSRicky Rusydi Satriawan
Ricky Rusydi Satriawan
IAIrfani Ryan Ardiansyah
Irfani Ryan Ardiansyah
ISI Ketut Agus Suanjaya
I Ketut Agus Suanjaya
Background Gliomas, particularly glioblastomas, have grim prognoses, necessitating early diagnostic and prognostic indicators. MicroRNAs (miRNAs), influential in cancer research, show potential as glioma biomarkers. This systematic review aimed to examine the efficacy of miRNAs in the diagnosis and prognosis of high-grade glioma. Methods A comprehensive search was conducted of PubMed, EMBASE, Cochrane Library, and Web of Science for studies published from 2013 to 2023. The eligibility criteria included high-grade glioma, histopathological confirmation, miRNA samples from cerebrospinal fluid or plasma, and relevant outcome data. Studies were excluded if they were experimental or reviews and not in English. Results Of the 1120 initial results, 8 studies involving 660 subjects met the inclusion criteria. Several studies have assessed miRNA expression and its association with diagnosis and prognosis of high-grade gliomas. Overexpression of miR-221, miR-222, miR-210, miR-21, miR-125b, and miR-223 and under-expression of miR-15b and miR-124-3p showed significant potential in differentiating high-grade glioma patients from controls. Additionally, miRNAs are associated with distinct tumorigenic pathways. Conclusion Elevated or depressed expression levels of specific circulating miRNAs hold significant promise as noninvasive biomarkers for the diagnosis and prognosis of high-grade glioma. These miRNAs offer valuable insights into disease progression and patient outcome. Further validation through extensive clinical trials and in-depth mechanistic studies is essential to realize their full clinical utility.

1 January 2024 in Korean Journal of Neurotrauma
Verified
Journal Article
Open access
PDF file
HTHanif Gordang Tobing
Hanif Gordang Tobing
FSFabianto Santoso
Fabianto Santoso
RSRicky Rusydi Satriawan
Ricky Rusydi Satriawan
ZNZharifah Fauziyyah Nafisah
Zharifah Fauziyyah Nafisah
BPBipatra Einstein Yacobus Paat
Bipatra Einstein Yacobus Paat
TWTheresia Meiske Laura Siscawati Wayne
Theresia Meiske Laura Siscawati Wayne
Tobing HG, et al. Korean J Neurotrauma. 2024 Jun;20(2):101-107. https://doi.org/10.13004/kjnt.2024.20.e22

15 July 2024 in F1000Research
Verified
Journal Article
Open access
PDF file
RARenindra Ananda Aman
Renindra Ananda Aman
MPMohammad Galih Pratama
Mohammad Galih Pratama
RSRicky Rusydi Satriawan
Ricky Rusydi Satriawan
IAIrfani Ryan Ardiansyah
Irfani Ryan Ardiansyah
ISI Ketut Agus Suanjaya
I Ketut Agus Suanjaya
* Background Gliomas, particularly glioblastomas, have grim prognoses, necessitating early diagnostic and prognostic indicators. MicroRNAs (miRNAs), influential in cancer research, show potential as glioma biomarkers. This systematic review aimed to examine the efficacy of miRNAs in the diagnosis and prognosis of high-grade glioma. Methods A comprehensive search was conducted of PubMed, EMBASE, Cochrane Library, and Web of Science for studies published from 2013 to 2023. The eligibility criteria included high-grade glioma, histopathological confirmation, miRNA samples from cerebrospinal fluid or plasma, and relevant outcome data. Studies were excluded if they were experimental or reviews and not in English. Results Of the 1120 initial results, 8 studies involving 660 subjects met the inclusion criteria. Several studies have assessed miRNA expression and its association with diagnosis and prognosis of high-grade gliomas. Overexpression of miR-221, miR-222, miR-210, miR-21, miR-125b, and miR-223 and under-expression of miR-15b and miR-124-3p showed significant potential in differentiating high-grade glioma patients from controls. Additionally, miRNAs are associated with distinct tumorigenic pathways. Conclusion Elevated or depressed expression levels of specific circulating miRNAs hold significant promise as noninvasive biomarkers for the diagnosis and prognosis of high-grade glioma. These miRNAs offer valuable insights into disease progression and patient outcome. Further validation through extensive clinical trials and in-depth mechanistic studies is essential to realize their full clinical utility.